KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Change in Receivables (2018 - 2025)

Historic Change in Receivables for Castle Biosciences (CSTL) over the last 8 years, with Q3 2025 value amounting to -$1.9 million.

  • Castle Biosciences' Change in Receivables fell 14492.24% to -$1.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $165000.0, marking a year-over-year decrease of 9873.32%. This contributed to the annual value of $12.6 million for FY2024, which is 1531.82% down from last year.
  • Per Castle Biosciences' latest filing, its Change in Receivables stood at -$1.9 million for Q3 2025, which was down 14492.24% from -$3.9 million recorded in Q2 2025.
  • In the past 5 years, Castle Biosciences' Change in Receivables registered a high of $5.8 million during Q3 2023, and its lowest value of -$3.9 million during Q2 2025.
  • Moreover, its 5-year median value for Change in Receivables was $2.7 million (2022), whereas its average is $2.0 million.
  • Its Change in Receivables has fluctuated over the past 5 years, first crashed by 85833.33% in 2021, then surged by 1150200.0% in 2023.
  • Over the past 5 years, Castle Biosciences' Change in Receivables (Quarter) stood at -$1.5 million in 2021, then surged by 137.09% to $540000.0 in 2022, then surged by 113.15% to $1.2 million in 2023, then tumbled by 33.19% to $769000.0 in 2024, then plummeted by 348.5% to -$1.9 million in 2025.
  • Its Change in Receivables stands at -$1.9 million for Q3 2025, versus -$3.9 million for Q2 2025 and $5.2 million for Q1 2025.